Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sex and anti-inflammatory treatment affect outcome of melanoma and non-small cell lung cancer patients with rheumatic immune-related adverse events.
Gente K, Diekmann L, Daniello L, Will J, Feisst M, Olsavszky V, Günther J, Lorenz HM, Souto-Carneiro MM, Hassel JC, Christopoulos P, Leipe J. Gente K, et al. Among authors: christopoulos p. J Immunother Cancer. 2023 Sep;11(9):e007557. doi: 10.1136/jitc-2023-007557. J Immunother Cancer. 2023. PMID: 37730272 Free PMC article.
EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer.
Christopoulos P, Endris V, Bozorgmehr F, Elsayed M, Kirchner M, Ristau J, Buchhalter I, Penzel R, Herth FJ, Heussel CP, Eichhorn M, Muley T, Meister M, Fischer JR, Rieken S, Warth A, Bischoff H, Schirmacher P, Stenzinger A, Thomas M. Christopoulos P, et al. Int J Cancer. 2018 Jun 15;142(12):2589-2598. doi: 10.1002/ijc.31275. Epub 2018 Jan 24. Int J Cancer. 2018. PMID: 29363116 Free article.
Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy.
Bernhardt D, Aufderstrasse S, König L, Adeberg S, Bozorgmehr F, Christopoulos P, Shafie RAE, Hörner-Rieber J, Kappes J, Thomas M, Herth F, Steins M, Debus J, Rieken S. Bernhardt D, et al. Among authors: christopoulos p. Cancer Manag Res. 2018 Nov 30;10:6563-6569. doi: 10.2147/CMAR.S180990. eCollection 2018. Cancer Manag Res. 2018. PMID: 30555261 Free PMC article.
Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors.
Rheinheimer S, Heussel CP, Mayer P, Gaissmaier L, Bozorgmehr F, Winter H, Herth FJ, Muley T, Liersch S, Bischoff H, Kriegsmann M, El Shafie RA, Stenzinger A, Thomas M, Kauczor HU, Christopoulos P. Rheinheimer S, et al. Among authors: christopoulos p. Cancers (Basel). 2020 Apr 23;12(4):1046. doi: 10.3390/cancers12041046. Cancers (Basel). 2020. PMID: 32340408 Free PMC article.
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma.
Budczies J, Kirchner M, Kluck K, Kazdal D, Glade J, Allgäuer M, Kriegsmann M, Heußel CP, Herth FJ, Winter H, Meister M, Muley T, Goldmann T, Fröhling S, Wermke M, Waller CF, Tufman A, Reck M, Peters S, Schirmacher P, Thomas M, Christopoulos P, Stenzinger A. Budczies J, et al. Among authors: christopoulos p. Cancer Immunol Immunother. 2022 Feb;71(2):251-265. doi: 10.1007/s00262-021-02981-w. Epub 2021 Jun 14. Cancer Immunol Immunother. 2022. PMID: 34125345 Free PMC article.
Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.
Christopoulos P, Bozorgmehr F, Brückner L, Chung I, Krisam J, Schneider MA, Stenzinger A, Eickhoff R, Mueller DW, Thomas M. Christopoulos P, et al. BMC Cancer. 2021 Jun 28;21(1):743. doi: 10.1186/s12885-021-08460-w. BMC Cancer. 2021. PMID: 34182952 Free PMC article. Clinical Trial.
Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer.
Daniello L, Elshiaty M, Bozorgmehr F, Kuon J, Kazdal D, Schindler H, Shah R, Volckmar AL, Lusky F, Diekmann L, Liersch S, Faehling M, Muley T, Kriegsmann M, Benesova K, Stenzinger A, Thomas M, Christopoulos P. Daniello L, et al. Among authors: christopoulos p. Front Oncol. 2021 Jun 29;11:703893. doi: 10.3389/fonc.2021.703893. eCollection 2021. Front Oncol. 2021. PMID: 34268127 Free PMC article.
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
Mountzios G, Samantas E, Senghas K, Zervas E, Krisam J, Samitas K, Bozorgmehr F, Kuon J, Agelaki S, Baka S, Athanasiadis I, Gaissmaier L, Elshiaty M, Daniello L, Christopoulou A, Pentheroudakis G, Lianos E, Linardou H, Kriegsmann K, Kosmidis P, El Shafie R, Kriegsmann M, Psyrri A, Andreadis C, Fountzilas E, Heussel CP, Herth FJ, Winter H, Emmanouilides C, Oikonomopoulos G, Meister M, Muley T, Bischoff H, Saridaki Z, Razis E, Perdikouri EI, Stenzinger A, Boukovinas I, Reck M, Syrigos K, Thomas M, Christopoulos P. Mountzios G, et al. Among authors: christopoulos p. ESMO Open. 2021 Oct;6(5):100254. doi: 10.1016/j.esmoop.2021.100254. Epub 2021 Sep 1. ESMO Open. 2021. PMID: 34481329 Free PMC article.
Distinct immune-effector and metabolic profile of CD8+ T cells in patients with autoimmune polyarthritis induced by therapy with immune checkpoint inhibitors.
Benesova K, Kraus FV, Carvalho RA, Lorenz H, Hörth CH, Günther J, Klika KD, Graf J, Diekmann L, Schank T, Christopoulos P, Hassel JC, Lorenz HM, Souto-Carneiro M. Benesova K, et al. Among authors: christopoulos p. Ann Rheum Dis. 2022 Aug 3;81(12):1730-41. doi: 10.1136/ard-2022-222451. Online ahead of print. Ann Rheum Dis. 2022. PMID: 35922125 Free PMC article.
294 results